Characterization of Circulating and Tumor-infiltrating Immune Cells in Malignant Brain Tumors

Launched by PIETRO MORTINI, MD, PROF. · Apr 14, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the immune cells in patients with malignant brain tumors, which are serious growths in the brain that can be either primary (starting in the brain) or metastatic (spreading from other parts of the body). The goal is to understand how these immune cells behave in the blood and within the tumors, and how this information relates to the patients' treatment outcomes. By analyzing blood samples and tumor tissue before surgery and during a year of follow-up, researchers hope to gain insights that could help improve future treatments.

To participate in this study, individuals must be adults aged 18 or older who have been diagnosed with a malignant brain tumor and are scheduled for surgery. Participants should be able to give their consent and understand the study requirements. Those who join can expect to provide blood samples before their surgery and will be monitored for a year afterward, along with additional tumor sampling for analysis. This study is currently recruiting participants, and everyone, regardless of gender, is welcome to apply as long as they meet the eligibility criteria.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • Adult patients (≥18 years)
• • Able to express informed consent
• • With primary or secondary malignant brain tumor
• • Requiring neurosurgical treatment (radiosurgery, stereotactic biopsy, surgery)
• Exclusion Criteria:
• • Patients who do not meet inclusion criteria.